Increased authorized by CMED follows the accumulated inflation of 12 months and will affect most regulated drugs in Brazil
From April, drug prices in Brazil will rise up to 5.06%as determined by the (Medicines Regulation Chamber), a body linked to (National Health Surveillance Agency).
This increase is based on the IPCA (National Consumer Price Index), which calculates inflation of the last 12 months, until February 2025. CMED will disclose, until Monday (31.mar), what will be the authorized prices for the readjustment, which will start to be valid on April 1st.
This adjustment will affect most regulated drugs in the country. However, the impact of the increase may vary from competition in the market. Drugs with greater supply, such as generic and similar, tend to have smaller increases. Patented medications with few available alternatives can record higher adjustments.
Average readjustment
The average readjustment will be 3.48%. Although this value is below inflation, the final prices may vary greatly. This is because the readjustment focuses on the PMC (maximum price to the consumer), which defines the maximum allowed value for the sale of medicines.
Lélio Souza, vice president of medical practice solutions, says many medicines are sold below this ceiling, which results in differences in prices practiced by pharmacies.
“Although the average readjustment is 3.48%, the consumer can find large price variations. In 2024, for example, some drugs had increases over 300%. This was the case of Rivaroxabana, an anticoagulant, which was priced ranging up to 359%during the year.”explains Souza.
The data is from the “ClickFarma” platform, which compares drug prices, based on lower monthly prices recorded among partner pharmacies.
